Trial
NCT02999633
Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
—
Condition
T-cell Type Acute Leukemia-Precursor
Intervention
Isatuximab SAR650984
Why stopped
Due to an unsatisfactory benefit/risk ratio, as specified in \& 14.8.1 of the protocol, Sanofi decided to stop enrollment and terminate ACT14596 prematurely
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-21